Main Menu Jump to Page


Retainer Agreement
info@rosenlegal.com

Aclaris shareholders have an opportunity to recover their investment losses.

Click "Join This Class Action" above.

Attorneys

Aclaris Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders Aclaris Therapeutics, Inc. (NASDAQ: ACRS) resulting from allegations that Aclaris may have issued materially misleading business information to the investing public.

If you purchased Aclaris securities and would like to join the action, please click "Join This Class Action," above.

Press Release

Rosen, a Top Ranked Law Firm, Announces Investigation of Securities Claims Against Aclaris Therapeutics, Inc. - ACRS

New York, N.Y., June 21, 2019. Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders Aclaris Therapeutics, Inc. (NASDAQ: ACRS) resulting from allegations that Aclaris may have issued materially misleading business information to the investing public.

On June 20, 2019, it was reported that the U.S. Food & Drug Administration (“FDA”) stated that an advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” regarding the product’s risk and efficacy. Specifically, the FDA stated that “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders . . . in the case of exposure to the eye and severe skin reactions including scarring.” On this news, Aclaris’s stock price fell $0.57, or over 11%, over the next two trading days to close at $4.54 on June 21, 2019.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Aclaris investors. If you purchased shares of Aclaris please visit the firm’s website at http://www.rosenlegal.com/cases-register-1606.html to join the class action. You may also contact Phillip Kim Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney advertising. Prior results do not guarantee future outcomes.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      cases@rosenlegal.com
      www.rosenlegal.com